138 related articles for article (PubMed ID: 26108715)
1. Androgen Receptor Targeted Conjugate for Bimodal Photodynamic Therapy of Prostate Cancer in Vitro.
Rapozzi V; Ragno D; Guerrini A; Ferroni C; della Pietra E; Cesselli D; Castoria G; Di Donato M; Saracino E; Benfenati V; Varchi G
Bioconjug Chem; 2015 Aug; 26(8):1662-71. PubMed ID: 26108715
[TBL] [Abstract][Full Text] [Related]
2. Oxime-based 19-nortestosterone-pheophorbide a conjugate: bimodal controlled release concept for PDT.
Pavlíčková V; Jurášek M; Rimpelová S; Záruba K; Sedlák D; Šimková M; Kodr D; Staňková E; Fähnrich J; Rottnerová Z; Bartůněk P; Lapčík O; Drašar P; Ruml T
J Mater Chem B; 2019 Sep; 7(36):5465-5477. PubMed ID: 31414695
[TBL] [Abstract][Full Text] [Related]
3. A photodynamic bifunctional conjugate for prostate cancer: an in vitro mechanistic study.
Rapozzi V; Varchi G; Della Pietra E; Ferroni C; Xodo LE
Invest New Drugs; 2017 Feb; 35(1):115-123. PubMed ID: 27726093
[TBL] [Abstract][Full Text] [Related]
4. Photodynamic therapy using pheophorbide and 670nm LEDs exhibits anti-cancer effects in-vitro in androgen dependent prostate cancer.
Gheewala T; Skwor T; Munirathinam G
Photodiagnosis Photodyn Ther; 2018 Mar; 21():130-137. PubMed ID: 29102652
[TBL] [Abstract][Full Text] [Related]
5. Pheophorbide-a conjugates with cancer-targeting moieties for targeted photodynamic cancer therapy.
You H; Yoon HE; Jeong PH; Ko H; Yoon JH; Kim YC
Bioorg Med Chem; 2015 Apr; 23(7):1453-62. PubMed ID: 25753328
[TBL] [Abstract][Full Text] [Related]
6. Conjugated PDT drug: photosensitizing activity and tissue distribution of PEGylated pheophorbide a.
Rapozzi V; Zacchigna M; Biffi S; Garrovo C; Cateni F; Stebel M; Zorzet S; Bonora GM; Drioli S; Xodo LE
Cancer Biol Ther; 2010 Sep; 10(5):471-82. PubMed ID: 20592494
[TBL] [Abstract][Full Text] [Related]
7. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
8. Vitamin Bc -Bearing Hydrophilic Photosensitizer Conjugate for Photodynamic Cancer Theranostics.
Kim J; Kim KS; Park SJ; Na K
Macromol Biosci; 2015 Aug; 15(8):1081-90. PubMed ID: 25829050
[TBL] [Abstract][Full Text] [Related]
9. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
10. Tailoring protease-sensitive photodynamic agents to specific disease-associated enzymes.
Gabriel D; Campo MA; Gurny R; Lange N
Bioconjug Chem; 2007; 18(4):1070-7. PubMed ID: 17477499
[TBL] [Abstract][Full Text] [Related]
11. Photosensitizer conjugated iron oxide nanoparticles for simultaneous in vitro magneto-fluorescent imaging guided photodynamic therapy.
Nafiujjaman M; Revuri V; Nurunnabi M; Cho KJ; Lee YK
Chem Commun (Camb); 2015 Apr; 51(26):5687-90. PubMed ID: 25715169
[TBL] [Abstract][Full Text] [Related]
12. Polyelectrolyte nanocomplex formation of heparin-photosensitizer conjugate with polymeric scavenger for photodynamic therapy.
Li L; Cho H; Kim S; Kang HC; Huh KM
Carbohydr Polym; 2015 May; 121():122-31. PubMed ID: 25659680
[TBL] [Abstract][Full Text] [Related]
13. Nitric oxide-mediated activity in anti-cancer photodynamic therapy.
Rapozzi V; Della Pietra E; Zorzet S; Zacchigna M; Bonavida B; Xodo LE
Nitric Oxide; 2013 Apr; 30():26-35. PubMed ID: 23357401
[TBL] [Abstract][Full Text] [Related]
14. Photoinduced cytotoxicity and biodistribution of prostate cancer cell-targeted porphyrins.
Sehgal I; Sibrian-Vazquez M; Vicente MG
J Med Chem; 2008 Oct; 51(19):6014-20. PubMed ID: 18839477
[TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy induced cell death of hormone insensitive prostate cancer PC-3 cells with autophagic characteristics.
Xu DD; Lam HM; Hoeven R; Xu CB; Leung AW; Cho WC
Photodiagnosis Photodyn Ther; 2013 Sep; 10(3):278-87. PubMed ID: 23993854
[TBL] [Abstract][Full Text] [Related]
16. Proteomic analysis reveals that pheophorbide a-mediated photodynamic treatment inhibits prostate cancer growth by hampering GDP-GTP exchange of ras-family proteins.
Xu DD; Xu CB; Lam HM; Wong FL; Leung AWN; Leong MML; Cho WCS; Hoeven R; Lv Q; Rong R
Photodiagnosis Photodyn Ther; 2018 Sep; 23():35-39. PubMed ID: 29800714
[TBL] [Abstract][Full Text] [Related]
17. Pyropheophorbide A and c(RGDyK) comodified chitosan-wrapped upconversion nanoparticle for targeted near-infrared photodynamic therapy.
Zhou A; Wei Y; Wu B; Chen Q; Xing D
Mol Pharm; 2012 Jun; 9(6):1580-9. PubMed ID: 22533630
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogenic and growth inhibitory effects of ring-substituted analogs of 3,3'-diindolylmethane (ring-DIMs) in hormone-responsive LNCaP human prostate cancer cells.
Abdelbaqi K; Lack N; Guns ET; Kotha L; Safe S; Sanderson JT
Prostate; 2011 Sep; 71(13):1401-12. PubMed ID: 21321979
[TBL] [Abstract][Full Text] [Related]
19. Pheophorbide a-mediated sonodynamic, photodynamic and sonophotodynamic therapies against prostate cancer.
Aksel M; Bozkurt-Girit O; Bilgin MD
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101909. PubMed ID: 32619716
[TBL] [Abstract][Full Text] [Related]
20. Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
Yoshida T; Kinoshita H; Segawa T; Nakamura E; Inoue T; Shimizu Y; Kamoto T; Ogawa O
Cancer Res; 2005 Nov; 65(21):9611-6. PubMed ID: 16266977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
